Novo Nordisk (NVO) announced Friday that the U.S. Food and Drug Administration (FDA) accepted its marketing application for an oral formulation of its weight loss therapy Wegovy (semaglutide) for ...
Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn, with ...
Novo Nordisk's 2024 earnings exceeded estimates, with 25% revenue growth and strong performance in diabetes, obesity, and rare disease segments. The market overreacted to CagriSema trial results, ...
And one of them is pharmaceutical giant Pfizer ( PFE 0.04%). Now, with a major step along the path to entering this ...
Novo Nordisk A/S’ (NYSE:NVO) Canada unit on Thursday announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide ...
Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...
JOHANNESBURG, Aug 14 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up ...
Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback